Krystal Biotech (FRA:4KB) Total Equity: €1,104.4 Mil (As of Mar. 2026)


FRA:4KB Krystal Biotech Inc FRA:4KB
58 GF Score
Price €313.40
GF Value €262.63
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Krystal Biotech Total Equity?

Krystal Biotech FRA:4KB +3.23% 58 Total Equity is €1,104.4 Mil as of Mar. 2026. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €262.63 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Krystal Biotech's total equity for the quarter that ended in Mar. 2026 was €1,104.4 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Krystal Biotech Total Equity Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech Total Equity Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 525.32 492.99 714.01 903.79 1,041.50

Krystal Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 910.82 902.24 969.47 1,041.50 1,104.37
FRA:4KB
58GF Score
Krystal Biotech Inc FRA:4KB
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Krystal Biotech's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1139.06-97.556
=1,041.5

Krystal Biotech's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=1208.376-104.006
=1,104.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,104.4 Mil mean?
Krystal Biotech (FRA:4KB) has a Total Equity of €1,104.4 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Krystal Biotech and its competitors.
Is Krystal Biotech's Total Equity too high?
Krystal Biotech's current Total Equity is €1,104.4 Mil. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Total Equity compare to NUVL and PRAX?
Krystal Biotech's Total Equity of €1,104.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Krystal Biotech and its competitors. Krystal Biotech's current Total Equity is €1,104.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €262.63, compared to a current price of €313.40 — trading 19.3% above its estimated fair value. The current Total Equity is €1,104.4 Mil. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Total Equity is €1,104.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (FRA:4KB) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of €313.40 is trading 19.3% above its estimated GF Value™ of €262.63. GuruFocus considers Krystal Biotech to be Modestly Overvalued.

Key valuation signals for FRA:4KB:

  • Total Equity: €1,104.4 Mil
  • GF Value™: €262.63 vs. price of €313.40 (19.3% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Krystal Biotech Business Description

Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score

Get the complete analysis for FRA:4KB

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€313.40
Price
€262.63
GF Value